226 related articles for article (PubMed ID: 18218783)
1. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
Kovarik JM; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
[TBL] [Abstract][Full Text] [Related]
2. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
[TBL] [Abstract][Full Text] [Related]
4. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
Kovarik JM; Lu M; Riviere GJ; Barbet I; Maton S; Goldwater DR; Schmouder RL
Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
[TBL] [Abstract][Full Text] [Related]
5. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
[TBL] [Abstract][Full Text] [Related]
6. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
[TBL] [Abstract][Full Text] [Related]
7. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
Schmouder R; Serra D; Wang Y; Kovarik JM; DiMarco J; Hunt TL; Bastien MC
J Clin Pharmacol; 2006 Aug; 46(8):895-904. PubMed ID: 16855074
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.
Kovarik JM; Schmouder RL; Hartmann S; Riviere GJ; Picard F; Voss B; Weiss M; Wagner F; Schmidt HH
J Clin Pharmacol; 2006 Feb; 46(2):149-56. PubMed ID: 16432266
[TBL] [Abstract][Full Text] [Related]
9. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
10. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects.
Kovarik JM; Slade A; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
Br J Clin Pharmacol; 2008 Aug; 66(2):199-206. PubMed ID: 18507656
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of fingolimod phosphate in healthy participants.
Wu K; Mercier F; David OJ; Schmouder RL; Looby M
J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Széplaki G; Merkely B
Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
[TBL] [Abstract][Full Text] [Related]
14. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
Camm J; Hla T; Bakshi R; Brinkmann V
Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790
[TBL] [Abstract][Full Text] [Related]
15. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
[TBL] [Abstract][Full Text] [Related]
16. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical effect of isoprenaline infusion.
Brembilla-Perrot B; Muhanna I; Nippert M; Popovic B; Beurrier D; Houriez P; Terrier de la Chaise A; Claudon O; Louis P; Abdelaal A; State S; Andronache M; Suty-Selton C
Europace; 2005 Nov; 7(6):621-7. PubMed ID: 16216767
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
20. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Wang Y; Kraus G
Br J Clin Pharmacol; 2004 May; 57(5):586-91. PubMed ID: 15089811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
